OsseoLabs
Develops AI-driven personalized surgical implants using advanced 3D printing and proprietary porous architecture for maxillofacial, orthopedic, and cranial reconstruction.
- CEO / Founder
- Vikram Ahuja
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $4.05M
- Latest Round
- Venture Round
- Key Investors
- Texas Medical Center,Plug and Play Tech Center,MedTech Innovator,Finno Efra Accelerator,Program Management Unit for Competitiveness (PMUC)
Technology & Products
Key Products
AI-driven personalized 3D-printed orthopedic and craniomaxillofacial (CMF) implants, including the OsseoVision™ platform for automated surgical planning and OsseoMatrix™ porous architecture.
Technological Advantage
CLAIMED: Proprietary OsseoMatrix™ porous architecture with functionally graded porosity design mimicking natural bone; OsseoVision™ AI-based surgical planning platform with automated workflows; proprietary Two-step Topology Framework enabling design and material customization. VERIFIED (via surgeon testimonials): 30% reduction in operative time, faster patient recovery with earlier weight-bearing, 0% post-operative complication rate across 320+ cases.
Differentiation
Value Proposition
Patient-specific implants that improve surgical accuracy, reduce operating time, and enhance clinical outcomes through AI-driven surgical planning automation
How They Differentiate
AI-driven OsseoVision™ platform for automated surgical planning and personalized implant design; patented OsseoMatrix™ porous architecture optimizing bio-integration; proprietary Two-step Topology Framework enabling material customization; clinical validation showing 30% surgery time reduction and 0% complication rate.
Market & Competition
Target Customers
Hospitals, surgical centers, orthopedic and maxillofacial surgeons
Industry Verticals
Medical devices; Healthcare; Surgical services
Competitors
Meticuly, Bioventus, DePuy Synthes, Impulse Monitoring
Growth & Milestones
Growth Metrics
Established partnerships with over 20 hospitals in Thailand; Expanded into the US market in 2024 with partnerships across over 20 US hospitals; 170+ pilot surgeries in 35+ hospitals; 28 patents and 37 products; ISO13485-certified manufacturing; FDA & CE approvals targeted for Q4 2025
Major Milestones
Spin-off from KMUTT (King Mongkut's University of Technology Thonburi); developed patented TPMS© porous architecture for dental and orthopedic implants; obtained worldwide patent on TPMS© technology; quality policy certification for personalized mandible reconstruction plates and cutting guides; location: 126 Pracha Uthit Rd., Bang Mod, Thung Khru, Bangkok 10140
Notable Customers
Faculty of Dentistry at Chulalongkorn University, Phramongkutklao Hospital (Department of Orthopedics), Rajavithi Hospital, Ramathibodi Hospital
Recent coverage of OsseoLabs
Funding rounds
- Grant$2,000,000
- Venture Round$50,000